Evercore ISI Reiterates Buy Rating on ProQR Therapeutics
ProQR Therapeutics received a reiterated 'buy' rating from Evercore ISI with a $6 price target, a 222.58% upside from the current price.
Key Points
- Evercore ISI Group reiterated its 'buy' rating on ProQR Therapeutics with a $6 price target on June 29, 2026.
- Evercore ISI Group's $6 price target implies 222.58% upside from ProQR Therapeutics N.V.'s ($PRQR) current $1.86 share price.
- Shares of NasdaqCM:PRQR traded near $1.53 on Monday, with a market cap of around $161.2 million.
- ProQR focuses on RNA editing technologies for genetic disorders and recently saw insider buying by Hinsch Gylvin Lykke.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Evercore ISI Group reiterated its 'buy' rating on ProQR Therapeutics N.V. (NasdaqCM:PRQR) on June 29, 2026, maintaining a price target of $6. Shares were trading near $1.53 on Monday.
Evercore ISI Group vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in ProQR Therapeutics
Several institutional investors have adjusted their positions in ProQR Therapeutics. Privium Fund Management B.V. increased its holdings by 109,387 shares, reaching a total of 5,467,149 shares valued at approximately $8.86 million. Aberdeen Group PLC also grew its stake, adding 366,289 shares for a total of 3,316,965 shares worth about $5.37 million. On the other hand, Sio Capital Management, LLC reduced its position by 209,466 shares, leaving it with 1,954,715 shares valued at $3.17 million.
ProQR Therapeutics N.V. Stock Down 18.8%
Shares of ProQR Therapeutics traded near $1.53 on Monday. The company, with a market cap of approximately $161.2 million, operates in the biotechnology sector. It has a beta of 0.061, indicating low volatility. The stock's 52-week range is between $1.33 and $3.10, with a 50-day moving average of $1.60 and a 200-day moving average of $1.90. ProQR maintains a current ratio of 2.48 and a quick ratio of 2.39, with a debt-to-equity ratio of 41.85.
$PRQR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
ProQR Therapeutics reported revenue of $13.64 million, though it experienced a revenue decline of 57.1%. The company has no net margin and a return on equity of -78.07%. Its next earnings release is scheduled for August 6, 2026.
Insider Buying and Selling at ProQR Therapeutics N.V.
On June 2, 2026, Hinsch Gylvin Lykke purchased 14,495 shares of ProQR Therapeutics, though the transaction was not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 29, 2026, Evercore ISI Group maintained its 'buy' rating on ProQR Therapeutics with a $6 price target. Similarly, on June 26, 2026, Jones Trading maintained its 'buy' rating with a $10 target, and Chardan Capital maintained its 'buy' rating with a $3 target. The consensus among analysts is a 'strong buy', with an average target price of $8.13 based on eight analyst opinions.
About ProQR Therapeutics
ProQR Therapeutics N.V. is a biotechnology firm based in Leiden, Netherlands. It focuses on developing RNA editing technologies to treat genetic disorders with unmet medical needs. The company's Axiomer RNA editing platform aims to provide innovative treatments for conditions such as cholestatic diseases, Rett syndrome, and metabolic dysfunction-associated steatohepatitis. Founded in 2012, ProQR collaborates with Eli Lilly and Company to explore new therapies for genetic disorders affecting the liver and nervous system.
Bottom Line
Evercore ISI Group's reiterated 'buy' rating for ProQR Therapeutics highlights continued confidence in the company's prospects. With a focus on pioneering RNA editing therapies, ProQR remains a key player in addressing genetic disorders. Investors should note that analyst ratings and targets reflect past data and may not indicate future performance.
Get ProQR Therapeutics N.V. alerts
New 13F filings, insider trades, and analyst moves on $PRQR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.